Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 476

1.

Correction: miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.

Minna E, Romeo P, Dugo M, De Cecco L, Todoerti K, Pilotti S, Perrone F, Seregni E, Agnelli L, Neri A, Greco A, Borrello MG.

Oncotarget. 2018 Feb 23;9(15):12534. doi: 10.18632/oncotarget.24557. eCollection 2018 Feb 23.

2.

Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?

Bossi P, Siano M, Bergamini C, Cossu Rocca M, Sponghini AP, Giannoccaro M, Tonella L, Paoli A, Marchesi E, Perrone F, Pilotti S, Locati LD, Canevari S, Licitra L, De Cecco L.

Dis Markers. 2017;2017:6870614. doi: 10.1155/2017/6870614. Epub 2017 Nov 12.

3.

Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury.

Magnaghi P, Salom B, Cozzi L, Amboldi N, Ballinari D, Tamborini E, Gasparri F, Montagnoli A, Raddrizzani L, Somaschini A, Bosotti R, Orrenius C, Bozzi F, Pilotti S, Galvani A, Sommer J, Stacchiotti S, Isacchi A.

Mol Cancer Ther. 2018 Mar;17(3):603-613. doi: 10.1158/1535-7163.MCT-17-0324. Epub 2017 Dec 13.

PMID:
29237806
4.

In situ hybridization detection methods for HPV16 E6/E7 mRNA in identifying transcriptionally active HPV infection of oropharyngeal carcinoma: an updating.

Volpi CC, Ciniselli CM, Gualeni AV, Plebani M, Alfieri S, Verderio P, Locati L, Perrone F, Quattrone P, Carbone A, Pilotti S, Gloghini A.

Hum Pathol. 2018 Apr;74:32-42. doi: 10.1016/j.humpath.2017.09.011. Epub 2017 Oct 6.

PMID:
28993274
5.

Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue.

Urbini M, Astolfi A, Indio V, Tarantino G, Serravalle S, Saponara M, Nannini M, Gronchi A, Fiore M, Maestro R, Brenca M, Dei Tos AP, Dagrada GP, Negri T, Pilotti S, Casali PG, Biasco G, Pession A, Stacchiotti S, Pantaleo MA.

Oncotarget. 2017 May 17;8(36):60036-60045. doi: 10.18632/oncotarget.17958. eCollection 2017 Sep 1.

6.

β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression.

Colombo C, Belfiore A, Paielli N, De Cecco L, Canevari S, Laurini E, Fermeglia M, Pricl S, Verderio P, Bottelli S, Fiore M, Stacchiotti S, Palassini E, Gronchi A, Pilotti S, Perrone F.

Mol Oncol. 2017 Nov;11(11):1495-1507. doi: 10.1002/1878-0261.12101. Epub 2017 Sep 29.

7.

New transcriptional-based insights into the pathogenesis of desmoplastic small round cell tumors (DSRCTs).

Negri T, Brich S, Bozzi F, Volpi CV, Gualeni AV, Stacchiotti S, De Cecco L, Canevari S, Gloghini A, Pilotti S.

Oncotarget. 2017 May 16;8(20):32492-32504. doi: 10.18632/oncotarget.16477.

8.

HSPA8 as a novel fusion partner of NR4A3 in extraskeletal myxoid chondrosarcoma.

Urbini M, Astolfi A, Pantaleo MA, Serravalle S, Dei Tos AP, Picci P, Indio V, Sbaraglia M, Benini S, Righi A, Gambarotti M, Gronchi A, Colombo C, Dagrada GP, Pilotti S, Maestro R, Polano M, Saponara M, Tarantino G, Pession A, Biasco G, Casali PG, Stacchiotti S.

Genes Chromosomes Cancer. 2017 Jul;56(7):582-586. doi: 10.1002/gcc.22462. Epub 2017 May 4.

PMID:
28383167
9.

Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.

Stacchiotti S, Saponara M, Frapolli R, Tortoreto M, Cominetti D, Provenzano S, Negri T, Dagrada GP, Gronchi A, Colombo C, Vincenzi B, Badalamenti G, Zuco V, Renne SL, Collini P, Morosi C, Dei Tos AP, Bello E, Pilotti S, Casali PG, D'Incalci M, Zaffaroni N.

Eur J Cancer. 2017 May;76:84-92. doi: 10.1016/j.ejca.2017.02.002. Epub 2017 Mar 8.

PMID:
28284173
10.

Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group.

Stacchiotti S, Gronchi A, Fossati P, Akiyama T, Alapetite C, Baumann M, Blay JY, Bolle S, Boriani S, Bruzzi P, Capanna R, Caraceni A, Casadei R, Colia V, Debus J, Delaney T, Desai A, Dileo P, Dijkstra S, Doglietto F, Flanagan A, Froelich S, Gardner PA, Gelderblom H, Gokaslan ZL, Haas R, Heery C, Hindi N, Hohenberger P, Hornicek F, Imai R, Jeys L, Jones RL, Kasper B, Kawai A, Krengli M, Leithner A, Logowska I, Martin Broto J, Mazzatenta D, Morosi C, Nicolai P, Norum OJ, Patel S, Penel N, Picci P, Pilotti S, Radaelli S, Ricchini F, Rutkowski P, Scheipl S, Sen C, Tamborini E, Thornton KA, Timmermann B, Torri V, Tunn PU, Uhl M, Yamada Y, Weber DC, Vanel D, Varga PP, Vleggeert-Lankamp CLA, Casali PG, Sommer J.

Ann Oncol. 2017 Jun 1;28(6):1230-1242. doi: 10.1093/annonc/mdx054. Review.

11.

Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.

Uboldi S, Craparotta I, Colella G, Ronchetti E, Beltrame L, Vicario S, Marchini S, Panini N, Dagrada G, Bozzi F, Pilotti S, Galmarini CM, D'Incalci M, Gatta R.

BMC Cancer. 2017 Feb 6;17(1):107. doi: 10.1186/s12885-017-3091-1.

12.

MIF/CD74 axis is a target for novel therapies in colon carcinomatosis.

Bozzi F, Mogavero A, Varinelli L, Belfiore A, Manenti G, Caccia C, Volpi CC, Beznoussenko GV, Milione M, Leoni V, Gloghini A, Mironov AA, Leo E, Pilotti S, Pierotti MA, Bongarzone I, Gariboldi M.

J Exp Clin Cancer Res. 2017 Jan 23;36(1):16. doi: 10.1186/s13046-016-0475-z.

13.

Integrative miRNA-Gene Expression Analysis Enables Refinement of Associated Biology and Prediction of Response to Cetuximab in Head and Neck Squamous Cell Cancer.

De Cecco L, Giannoccaro M, Marchesi E, Bossi P, Favales F, Locati LD, Licitra L, Pilotti S, Canevari S.

Genes (Basel). 2017 Jan 14;8(1). pii: E35. doi: 10.3390/genes8010035.

14.

A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.

Locati LD, Perrone F, Cortelazzi B, Bergamini C, Bossi P, Civelli E, Morosi C, Lo Vullo S, Imbimbo M, Quattrone P, Dagrada GP, Granata R, Resteghini C, Mirabile A, Alfieri S, Orlandi E, Mariani L, Saibene G, Pilotti S, Licitra L.

Eur J Cancer. 2016 Dec;69:158-165. doi: 10.1016/j.ejca.2016.09.022. Epub 2016 Nov 5.

PMID:
27821319
15.

Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment.

Tazzari M, Indio V, Vergani B, De Cecco L, Rini F, Negri T, Camisaschi C, Fiore M, Stacchiotti S, Dagrada GP, Casali PG, Gronchi A, Astolfi A, Pantaleo MA, Villa A, Lombardo C, Arienti F, Pilotti S, Rivoltini L, Castelli C.

J Invest Dermatol. 2017 Feb;137(2):484-493. doi: 10.1016/j.jid.2016.06.634. Epub 2016 Sep 5.

16.

Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework.

Bozzi F, Brich S, Dagrada GP, Negri T, Conca E, Cortelazzi B, Belfiore A, Perrone F, Gualeni AV, Gloghini A, Cabras A, Brenca M, Maestro R, Zaffaroni N, Casali P, Bertulli R, Deraco M, Pilotti S.

Oncotarget. 2016 Nov 15;7(46):75503-75517. doi: 10.18632/oncotarget.12262.

17.

Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma.

Bossi P, Resteghini C, Paielli N, Licitra L, Pilotti S, Perrone F.

Oncotarget. 2016 Nov 8;7(45):74362-74379. doi: 10.18632/oncotarget.11413. Review.

18.

Quadruple-Negative GIST Is a Sentinel for Unrecognized Neurofibromatosis Type 1 Syndrome.

Gasparotto D, Rossi S, Polano M, Tamborini E, Lorenzetto E, Sbaraglia M, Mondello A, Massani M, Lamon S, Bracci R, Mandolesi A, Frate E, Stanzial F, Agaj J, Mazzoleni G, Pilotti S, Gronchi A, Dei Tos AP, Maestro R.

Clin Cancer Res. 2017 Jan 1;23(1):273-282. doi: 10.1158/1078-0432.CCR-16-0152. Epub 2016 Jul 7.

19.

Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases.

Cassinelli G, Favini E, Dal Bo L, Tortoreto M, De Maglie M, Dagrada G, Pilotti S, Zunino F, Zaffaroni N, Lanzi C.

Oncotarget. 2016 Jul 26;7(30):47848-47863. doi: 10.18632/oncotarget.10292.

20.

Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database.

Stacchiotti S, Provenzano S, Dagrada G, Negri T, Brich S, Basso U, Brunello A, Grosso F, Galli L, Palassini E, Libertini M, Colia V, Gronchi A, Dei Tos AP, Crippa F, Morosi C, Pilotti S, Casali PG.

Ann Surg Oncol. 2016 Sep;23(9):2735-44. doi: 10.1245/s10434-016-5331-z. Epub 2016 Jun 22.

PMID:
27334221
21.

Sunitinib-induced morpho-functional changes and drug effectiveness in malignant solitary fibrous tumours.

Spagnuolo RD, Brich S, Bozzi F, Conca E, Castelli C, Tazzari M, Maestro R, Brenca M, Gualeni AV, Gloghini A, Stacchiotti S, Pierotti MA, Pilotti S, Negri T.

Oncotarget. 2016 Jul 19;7(29):45015-45026. doi: 10.18632/oncotarget.7523.

22.

Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma.

Perrone F, Bossi P, Cortelazzi B, Dagrada GP, Paielli N, Licitra L, Pilotti S.

Oral Oncol. 2016 Jul;58:e4-5. doi: 10.1016/j.oraloncology.2016.05.015. Epub 2016 Jun 1. No abstract available.

PMID:
27262592
23.

Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial-Mesenchymal Transition-like Process and 22q Loss.

Stacchiotti S, Astolfi A, Gronchi A, Fontana A, Pantaleo MA, Negri T, Brenca M, Tazzari M, Urbini M, Indio V, Colombo C, Radaelli S, Brich S, Dei Tos AP, Casali PG, Castelli C, Dagrada GP, Pilotti S, Maestro R.

Mol Cancer Res. 2016 Sep;14(9):820-9. doi: 10.1158/1541-7786.MCR-16-0068. Epub 2016 Jun 2.

24.

AKT1 and BRAF mutations in pediatric aggressive fibromatosis.

Meazza C, Belfiore A, Busico A, Settanni G, Paielli N, Cesana L, Ferrari A, Chiaravalli S, Massimino M, Gronchi A, Colombo C, Pilotti S, Perrone F.

Cancer Med. 2016 Jun;5(6):1204-13. doi: 10.1002/cam4.669. Epub 2016 Apr 8.

25.

Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab.

Bossi P, Bergamini C, Siano M, Cossu Rocca M, Sponghini AP, Favales F, Giannoccaro M, Marchesi E, Cortelazzi B, Perrone F, Pilotti S, Locati LD, Licitra L, Canevari S, De Cecco L.

Clin Cancer Res. 2016 Aug 1;22(15):3961-70. doi: 10.1158/1078-0432.CCR-15-2547. Epub 2016 Feb 26.

26.

miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.

Minna E, Romeo P, Dugo M, De Cecco L, Todoerti K, Pilotti S, Perrone F, Seregni E, Agnelli L, Neri A, Greco A, Borrello MG.

Oncotarget. 2016 Mar 15;7(11):12731-47. doi: 10.18632/oncotarget.7262. Review. Erratum in: Oncotarget. 2018 Feb 23;9(15):12534.

27.

Reproducibility between messenger RNA real-time polymerase chain reaction and messenger RNA in situ hybridization in oropharyngeal squamous cell carcinoma patients.

Ciniselli CM, Volpi CC, Cortelazzi B, Gualeni AV, Bottelli S, Perrone F, Pilotti S, Gloghini A, Verderio P.

Hum Pathol. 2016 Jan;47(1):157-8. doi: 10.1016/j.humpath.2015.06.026. Epub 2015 Oct 3. No abstract available.

PMID:
26527520
28.

Imatinib in advanced chordoma: A retrospective case series analysis.

Hindi N, Casali PG, Morosi C, Messina A, Palassini E, Pilotti S, Tamborini E, Radaelli S, Gronchi A, Stacchiotti S.

Eur J Cancer. 2015 Nov;51(17):2609-14. doi: 10.1016/j.ejca.2015.07.038. Epub 2015 Aug 14.

PMID:
26283036
29.

Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP).

Stacchiotti S, Pantaleo MA, Negri T, Astolfi A, Tazzari M, Dagrada GP, Urbini M, Indio V, Maestro R, Gronchi A, Fiore M, Dei Tos AP, Conca E, Palassini E, Vincenzi B, Grosso F, Pilotti S, Castelli C, Casali PG.

Clin Cancer Res. 2016 Feb 15;22(4):837-46. doi: 10.1158/1078-0432.CCR-15-1243. Epub 2015 Aug 10.

30.

Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation.

Dagrada GP, Spagnuolo RD, Mauro V, Tamborini E, Cesana L, Gronchi A, Stacchiotti S, Pierotti MA, Negri T, Pilotti S.

Mod Pathol. 2015 Aug;28(8):1074-83. doi: 10.1038/modpathol.2015.70. Epub 2015 May 29.

31.

Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report.

Tazzari M, Palassini E, Vergani B, Villa A, Rini F, Negri T, Colombo C, Crippa F, Morosi C, Casali PG, Pilotti S, Stacchiotti S, Rivoltini L, Castelli C.

BMC Cancer. 2015 Feb 14;15:58. doi: 10.1186/s12885-015-1044-0.

32.

High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma.

Sanfilippo R, Bertulli R, Marrari A, Fumagalli E, Pilotti S, Morosi C, Messina A, Dei Tos AP, Gronchi A, Casali PG.

Clin Sarcoma Res. 2014 Nov 22;4(1):16. doi: 10.1186/2045-3329-4-16. eCollection 2014.

33.

Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma.

Gronchi A, Collini P, Miceli R, Valeri B, Renne SL, Dagrada G, Fiore M, Sanfilippo R, Barisella M, Colombo C, Morosi C, Stacchiotti S, Casali PG, Dei Tos AP, Pilotti S.

Am J Surg Pathol. 2015 Mar;39(3):383-93. doi: 10.1097/PAS.0000000000000366.

PMID:
25581729
34.

Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers.

Locati LD, Perrone F, Cortelazzi B, Lo Vullo S, Bossi P, Dagrada G, Quattrone P, Bergamini C, Potepan P, Civelli E, Fallai C, Pilotti S, Licitra L.

Head Neck. 2016 May;38(5):724-31. doi: 10.1002/hed.23940. Epub 2015 Jun 25.

PMID:
25522335
35.

Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma.

Cortelazzi B, Verderio P, Ciniselli CM, Pizzamiglio S, Bossi P, Gloghini A, Gualeni AV, Volpi CC, Locati L, Pierotti MA, Licitra L, Pilotti S, Perrone F.

J Oral Pathol Med. 2015 Oct;44(9):734-45. doi: 10.1111/jop.12301. Epub 2014 Dec 14.

PMID:
25495427
36.

Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma.

Pricl S, Cortelazzi B, Dal Col V, Marson D, Laurini E, Fermeglia M, Licitra L, Pilotti S, Bossi P, Perrone F.

Mol Oncol. 2015 Feb;9(2):389-97. doi: 10.1016/j.molonc.2014.09.003. Epub 2014 Sep 26.

37.

Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.

Stacchiotti S, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G, Cominetti D, Morosi C, Dei Tos AP, Festinese F, Fumagalli E, Provenzano S, Gronchi A, Pennacchioli E, Negri T, Dagrada GP, Spagnuolo RD, Pilotti S, Casali PG, Zaffaroni N.

Eur J Cancer. 2014 Nov;50(17):3021-8. doi: 10.1016/j.ejca.2014.09.004. Epub 2014 Sep 27.

PMID:
25269954
38.

Oncogenic RAS-induced senescence in human primary thyrocytes: molecular effectors and inflammatory secretome involved.

Vizioli MG, Santos J, Pilotti S, Mazzoni M, Anania MC, Miranda C, Pagliardini S, Pierotti MA, Gil J, Greco A.

Oncotarget. 2014 Sep 30;5(18):8270-83.

39.

Identification of a gene expression driven progression pathway in myxoid liposarcoma.

De Cecco L, Negri T, Brich S, Mauro V, Bozzi F, Dagrada G, Disciglio V, Sanfilippo R, Gronchi A, D'Incalci M, Casali PG, Canevari S, Pierotti MA, Pilotti S.

Oncotarget. 2014 Aug 15;5(15):5965-77.

40.

Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy.

Tazzari M, Negri T, Rini F, Vergani B, Huber V, Villa A, Dagrada P, Colombo C, Fiore M, Gronchi A, Stacchiotti S, Casali PG, Pilotti S, Rivoltini L, Castelli C.

Br J Cancer. 2014 Sep 23;111(7):1350-62. doi: 10.1038/bjc.2014.437. Epub 2014 Aug 7.

41.

Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1.

Dossi R, Frapolli R, Di Giandomenico S, Paracchini L, Bozzi F, Brich S, Castiglioni V, Borsotti P, Belotti D, Uboldi S, Sanfilippo R, Erba E, Giavazzi R, Marchini S, Pilotti S, D'Incalci M, Taraboletti G.

Int J Cancer. 2015 Feb 1;136(3):721-9. doi: 10.1002/ijc.29023. Epub 2014 Jun 19.

42.

Ewing sarcoma of the small bowel: a study of seven cases, including one with the uncommonly reported EWSR1-FEV translocation.

Milione M, Gasparini P, Sozzi G, Mazzaferro V, Ferrari A, Casali PG, Perrone F, Tamborini E, Pellegrinelli A, Gherardi G, Arrigoni G, Collini P, Testi A, De Paoli E, Aiello A, Pilotti S, Pelosi G.

Histopathology. 2014 Jun;64(7):1014-26. doi: 10.1111/his.12350. Epub 2014 Feb 25.

PMID:
24898918
43.

Circulating free DNA in a screening program for early colorectal cancer detection.

Perrone F, Lampis A, Bertan C, Verderio P, Ciniselli CM, Pizzamiglio S, Frattini M, Nucifora M, Molinari F, Gallino G, Gariboldi M, Meroni E, Leo E, Pierotti MA, Pilotti S.

Tumori. 2014 Mar-Apr;100(2):115-21. doi: 10.1700/1491.16389.

PMID:
24852853
44.

miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma.

Minna E, Romeo P, De Cecco L, Dugo M, Cassinelli G, Pilotti S, Degl'Innocenti D, Lanzi C, Casalini P, Pierotti MA, Greco A, Borrello MG.

Oncotarget. 2014 May 15;5(9):2513-28.

45.

Activity of sunitinib in extraskeletal myxoid chondrosarcoma.

Stacchiotti S, Pantaleo MA, Astolfi A, Dagrada GP, Negri T, Dei Tos AP, Indio V, Morosi C, Gronchi A, Colombo C, Conca E, Toffolatti L, Tazzari M, Crippa F, Maestro R, Pilotti S, Casali PG.

Eur J Cancer. 2014 Jun;50(9):1657-64. doi: 10.1016/j.ejca.2014.03.013. Epub 2014 Apr 2.

PMID:
24703573
46.

Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy.

Locati LD, Perrone F, Cortelazzi B, Imbimbo M, Bossi P, Potepan P, Civelli E, Rinaldi G, Quattrone P, Licitra L, Pilotti S.

Cancer Biol Ther. 2014 Jun 1;15(6):678-82. doi: 10.4161/cbt.28410. Epub 2014 Mar 11.

47.

Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis.

Bossi P, Orlandi E, Miceli R, Perrone F, Guzzo M, Mariani L, Granata R, Locati L, Fallai C, Cortelazzi B, Pilotti S, Scaramellini G, Gloghini A, Licitra L.

Ann Oncol. 2014 Mar;25(3):694-9. doi: 10.1093/annonc/mdu004. Epub 2014 Feb 7.

48.

Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer.

Zanutto S, Pizzamiglio S, Ghilotti M, Bertan C, Ravagnani F, Perrone F, Leo E, Pilotti S, Verderio P, Gariboldi M, Pierotti MA.

Br J Cancer. 2014 Feb 18;110(4):1001-7. doi: 10.1038/bjc.2013.819. Epub 2014 Jan 14.

49.

Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.

Bozzi F, Manenti G, Conca E, Stacchiotti S, Messina A, Dagrada G, Gronchi A, Panizza P, Pierotti MA, Tamborini E, Pilotti S.

Neuro Oncol. 2014 Jan;16(1):72-80. doi: 10.1093/neuonc/not238.

50.

Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study.

Stacchiotti S, Dagrada GP, Sanfilippo R, Negri T, Vittimberga I, Ferrari S, Grosso F, Apice G, Tricomi M, Colombo C, Gronchi A, Dei Tos AP, Pilotti S, Casali PG.

Clin Sarcoma Res. 2013 Dec 18;3(1):16. doi: 10.1186/2045-3329-3-16.

Supplemental Content

Loading ...
Support Center